Co-Diagnostics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $622,489 | $3.9M | $6.8M | $34.2M | $97.9M |
| Gross profit | $400,112 | $2.9M | $2.6M | $28.7M | $86.3M |
| Operating income | -$50.2M | -$40.1M | -$42.7M | -$27.0M | $46.1M |
| Operating expenses | $50.6M | $43.0M | $45.3M | $55.7M | $40.2M |
| Cost of revenue | $222,377 | $999,124 | $4.2M | $5.5M | $11.6M |
| Cash from operations | -$29.1M | -$29.2M | -$22.1M | $6.6M | $41.1M |
| Capital expenditure | $700,047 | $748,352 | $1.4M | $1.4M | $669,463 |
| Free cash flow | -$29.8M | -$29.9M | -$23.4M | $5.1M | $40.4M |
| Share repurchases | — | — | $1.4M | $14.2M | — |
| Impairments | $18.9M | — | $0 | $15.4M | — |
| Total assets | $24.7M | $63.6M | $95.3M | $123.1M | $160.0M |
| Total liabilities | $4.1M | $9.7M | $9.3M | $8.6M | $25.6M |
Shares outstanding 3.6M · Free float 97.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.